NEOSAR Drug Patent Profile
✉ Email this page to a colleague
When do Neosar patents expire, and what generic alternatives are available?
Neosar is a drug marketed by Bedford and Teva Parenteral and is included in two NDAs.
The generic ingredient in NEOSAR is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neosar
A generic version of NEOSAR was approved as cyclophosphamide by BAXTER HLTHCARE on May 21st, 2008.
Summary for NEOSAR
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Clinical Trials: | 405 |
Patent Applications: | 4,560 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEOSAR at DailyMed |
Recent Clinical Trials for NEOSAR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Adam Kittai | Phase 2 |
Joseph Tuscano | Phase 2 |
ADC Therapeutics | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for NEOSAR
US Patents and Regulatory Information for NEOSAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bedford | NEOSAR | cyclophosphamide | INJECTABLE;INJECTION | 087442-004 | Jul 8, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Parenteral | NEOSAR | cyclophosphamide | INJECTABLE;INJECTION | 040015-005 | Apr 29, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bedford | NEOSAR | cyclophosphamide | INJECTABLE;INJECTION | 087442-002 | Feb 16, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |